Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Ultomiris approved in EU for gMG

Investegate announcements from AstraZeneca PLC, Ultomiris approved in EU for gMG

Related Keywords

Milan ,Lombardia ,Italy ,Japan ,United States ,United Kingdom ,Massachusetts ,China ,Boston ,Bonifati ,Calabria ,Portugal ,Sweden ,Ireland ,Cambridge ,Cambridgeshire ,America ,Swedish ,Republic Of Ireland ,Istituto Neurologico Carlo Besta ,Marc Dunoyer ,Adrian Kemp ,Renato Mantegazza ,National Organization For Rare Disorders ,Department Of Neuroimmunology ,European Commission ,Alexion Pharmaceuticals Inc ,Nasdaq ,Astrazeneca ,Committee For Medicinal Products Human ,Investor Relations Team ,National Institutes Of Neurological Disorders ,York Academy Of Sciences ,Medicinal Products ,Human Use ,Myasthenia Gravis Activities ,Daily Living Profile ,Neuromuscular Diseases ,Neurologico Carlo Besta ,Chief Executive Officer ,Japanin August ,North America ,Myasthenia Gravis Foundation ,America Clinical Classification Class ,Astrazeneca Rare Disease ,Alexion Pharmaceuticals ,Rare Diseases ,New York Academy ,Myasthenia Gravis ,Intern Med ,Myasthenia Gravis Epidemiology ,Northern Portugal ,Frequency Estimates ,Clinical Epidemiological Distribution ,Muscle Nerve ,European Product Information ,Ocular Myasthenia Gravis ,National Organization ,Rare Disorders ,Accessed March ,Clinical Overview ,Gravis Fact ,National Institutes ,Neurological Disorders ,Efficacy Study ,Adults With Generalized Myasthenia ,Investegate Announcements ,Investegate Company Announcements ,Astrazeneca Plc ,Egulatory News Service ,Egulatory News Service And Regulatory ,Ns ,